Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Eli Lilly will acquire Pasadena, California-based Protomer Technologies in a deal valued at more than $1 billion to add a glucose-responsive insulin program to…
Eli Lilly said on Wednesday it had acquired Protomer Technologies, a Pasadena-based startup developing glucose-responsive insulin, in a deal valued at more…
Eli Lilly is acquiring Protomer Technologies for upwards of $1 billion to add the startup's glucose-responsive insulin program and peptide engineering platform…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
Eli Lilly acquired Pasadena-based Protomer Technologies in a deal valued over $1 billion based on future development and commercial milestones. Lilly previously owned 14% of Protomer; the acquisition gives Lilly Protomer's peptide/protein engineering platform and glucose-sensing insulin program.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Eli Lilly and Company / Protomer Technologies (this deal) | 2021 | $1.0B | — |
| Eli Lilly and Company / Boehringer Ingelheim GmbH | 2011 | $444M | 89 |
| Eli Lilly and Company / Loxo Oncology, Inc. | 2019 | $8.0B | 88 |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Eli Lilly and Company / ICOS Corporation | 2006 | $2.3B | 87 |
| Eli Lilly and Company / Novartis Animal Health | 2014 | $5.4B | 70 |
| Eli Lilly and Company / Incyte Corporation | 2009 | $755M | 69 |
← Browse all deals · How we score deals
More: 2021 deals · Eli Lilly and Company deals · Metabolic deals